Free tool
FAERS Monitor: Maxalt
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020864 or its brand name (Maxalt, Rizatriptan Benzoate). Reports on generic versions are filed under their own applications.
Reports
9,569
Serious
5,593
58% of reports
Hospitalization
1,955
Death reported
175
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,547
- nausea1,200
- headache1,016
- off label use953
- migraine934
- product use in unapproved indication642
- fatigue609
- hyperhidrosis591
- pain568
- sedation498
- nightmare497
- nephrolithiasis457
- vomiting447
- diarrhoea419
- dizziness404
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 97 |
| 2005 | 101 |
| 2006 | 110 |
| 2007 | 119 |
| 2008 | 136 |
| 2009 | 169 |
| 2010 | 224 |
| 2011 | 301 |
| 2012 | 406 |
| 2013 | 349 |
| 2014 | 371 |
| 2015 | 537 |
| 2016 | 835 |
| 2017 | 487 |
| 2018 | 608 |
| 2019 | 767 |
| 2020 | 682 |
| 2021 | 594 |
| 2022 | 601 |
| 2023 | 512 |
| 2024 | 545 |
| 2025 | 526 |
| 2026 | 492 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,590 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| sedationSignal | 498 | 42.6 | 39.1 | 19,823 |
| nightmareSignal | 497 | 32.0 | 29.4 | 14,714 |
| nephrolithiasisSignal | 457 | 22.1 | 20.2 | 9,118 |
| migraineSignal | 934 | 21.7 | 20.4 | 18,333 |
| hyperhidrosisSignal | 591 | 10.1 | 9.4 | 4,860 |
| product use in unapproved indicationSignal | 642 | 5.7 | 5.3 | 2,510 |
| headacheSignal | 1,016 | 3.6 | 3.4 | 1,928 |
| nauseaSignal | 1,200 | 3.3 | 3.2 | 2,034 |
| drug ineffectiveSignal | 1,547 | 2.6 | 2.5 | 1,596 |
| off label useSignal | 953 | 2.4 | 2.3 | 805 |
| vomitingSignal | 447 | 2.1 | 1.9 | 259 |
| painSignal | 568 | 2.0 | 1.9 | 306 |
| dizziness | 404 | 1.8 | 1.6 | 141 |
| fatigue | 609 | 1.7 | 1.6 | 190 |
| diarrhoea | 419 | 1.4 | 1.3 | 55 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.